AdventHealth Global Robotics Institute, Florida, USA.
University of Central Florida (UCF), Florida, USA.
Int Braz J Urol. 2023 Nov-Dec;49(6):677-687. doi: 10.1590/S1677-5538.IBJU.2023.0467.
Salvage robotic-assisted radical prostatectomy (S-RARP) has gained prominence in recent years for treating patients with cancer recurrence following non-surgical treatments of Prostate Cancer. We conducted a systematic literature review to evaluate the role and outcomes of S-RARP over the past decade.
A systematic review was conducted, encompassing articles published between January 1st, 2013, and June 1st, 2023, on S-RARP outcomes. Articles were screened according to PRISMA guidelines, resulting in 33 selected studies. Data were extracted, including patient demographics, operative times, complications, functional outcomes, and oncological outcomes.
Among 1,630 patients from 33 studies, radiotherapy was the most common primary treatment (42%). Operative times ranged from 110 to 303 minutes, with estimated blood loss between 50 to 745 mL. Intraoperative complications occurred in 0 to 9% of cases, while postoperative complications ranged from 0 to 90% (Clavien 1-5). Continence rates varied (from 0 to 100%), and potency rates ranged from 0 to 66.7%. Positive surgical margins were reported up to 65.6%, and biochemical recurrence ranged from 0 to 57%.
Salvage robotic-assisted radical prostatectomy in patients with cancer recurrence after previous prostate cancer treatment is safe and feasible. The literature is based on retrospective studies with inherent limitations describing low rates of intraoperative complications and small blood loss. However, potency and continence rates are largely reduced compared to the primary RARP series, despite the type of the primary treatment. Better-designed studies to assess the long-term outcomes and individually specify each primary therapy impact on the salvage treatment are still needed. Future articles should be more specific and provide more details regarding the previous therapies and S-RARP surgical techniques.
挽救性机器人辅助根治性前列腺切除术(S-RARP)近年来在治疗前列腺癌非手术治疗后癌症复发的患者方面受到重视。我们进行了系统的文献回顾,以评估过去十年中 S-RARP 的作用和结果。
进行了系统的文献回顾,包括 2013 年 1 月 1 日至 2023 年 6 月 1 日期间发表的关于 S-RARP 结果的文章。根据 PRISMA 指南筛选文章,最终选择了 33 篇研究。提取的数据包括患者人口统计学、手术时间、并发症、功能结果和肿瘤学结果。
在 33 项研究的 1630 名患者中,最常见的主要治疗方法是放疗(42%)。手术时间范围为 110 至 303 分钟,估计失血量为 50 至 745 毫升。术中并发症发生率为 0 至 9%,术后并发症发生率为 0 至 90%(Clavien 1-5)。尿控率各不相同(0 至 100%),勃起功能率为 0 至 66.7%。报告的切缘阳性率高达 65.6%,生化复发率为 0 至 57%。
对于先前前列腺癌治疗后癌症复发的患者,挽救性机器人辅助根治性前列腺切除术是安全可行的。该文献基于描述术中并发症发生率低和失血量小的回顾性研究,但与原发性 RARP 系列相比,勃起功能和尿控率大大降低,尽管主要治疗方式不同。仍需要设计更好的研究来评估长期结果,并单独评估每种主要治疗方法对挽救治疗的影响。未来的文章应更具体,并提供有关先前治疗方法和 S-RARP 手术技术的更多详细信息。